Geron Corporation (GERN)
| Market Cap | 1.11B |
| Revenue (ttm) | 596,000 |
| Net Income (ttm) | -141.90M |
| Shares Out | 508.72M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 868,651 |
| Open | 2.25 |
| Previous Close | 2.23 |
| Day's Range | 2.18 - 2.26 |
| 52-Week Range | 1.18 - 3.84 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 5.10 (+133.41%) |
| Earnings Date | May 8, 2023 |
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte... [Read more]
Financial Performance
In 2022, Geron's revenue was $596,000, a decrease of -57.21% compared to the previous year's $1.39 million. Losses were -$141.90 million, 22.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 133.41% from the latest price.
News
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock a...
Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematolog...
Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 fina...
Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Execu...
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today highlighted multiple additions to its senior commercial leadership team...
Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of co...
Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consis...
Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes
Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.
Geron Corporation Announces Proposed Public Offering of Common Stock
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of i...
Why Is Geron (GERN) Stock Soaring 50% Today?
Though the major indices posted a strong recovery effort on Wednesday, late-stage clinical biopharmaceutical firm Geron (NASDAQ: GERN) soared above most public players. Following positive top-line re...
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical tr...
Geron Announces Conference Call for Top-Line Results from IMerge Phase 3
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imete...
Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced results from an oral presentation at the 64th American Societ...
Geron to Participate in Stifel 2022 Healthcare Conference
FOSTER CITY, Calif.
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS
FOSTER CITY, Calif.
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones
FOSTER CITY, Calif.
Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022
FOSTER CITY, Calif.
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
Here is how Geron (GERN) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have performed compared to their sector so far this year.
Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of...
Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignanci...
Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 s...
Geron Corporation Reports Second Quarter 2022 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematolog...